Literature DB >> 12065499

Synergic effects of mycoplasmal lipopeptides and extracellular ATP on activation of macrophages.

Takeshi Into1, Mari Fujita, Tsugumi Okusawa, Akira Hasebe, Manabu Morita, Ken-Ichiro Shibata.   

Abstract

Mycoplasmal lipopeptides S-(2,3-bispalmitoyloxypropyl)-CGDPKHSPKSF and S-(2,3-bispalmitoyloxypropyl)-CGNNDESNISFKEK activated a monocytic cell line, THP-1 cells, to produce tumor necrosis factor alpha. The activity of the lipopeptides was augmented by ATP in a dose-dependent manner. In addition, the level of expression of mRNAs for tumor necrosis factor alpha and interleukin-1 beta, -6, and -8 was also upregulated by the lipopeptides and/or extracellular ATP, but that of interleukin-10 was not. The P2X purinergic receptor antagonists pyridoxal phosphate 6-azophenyl 2',4'-disulfonic acid and periodate-oxidized ATP suppressed the activity of ATP to augment the activation of THP-1 cells by the lipopeptides, suggesting that P2X receptors play important roles in the activity of ATP. The nuclear factor kappa B inhibitor dexamethasone also suppressed the activity, suggesting that the activity of ATP is dependent upon the nuclear factor kappa B. Thus, these results suggest that the interaction of extracellular ATP with the P2X receptors is attributed to the activity of ATP to augment the activation of THP-1 cells by mycoplasmal lipopeptides.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12065499      PMCID: PMC128035          DOI: 10.1128/IAI.70.7.3586-3591.2002

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  49 in total

1.  Cutting edge: preferentially the R-stereoisomer of the mycoplasmal lipopeptide macrophage-activating lipopeptide-2 activates immune cells through a toll-like receptor 2- and MyD88-dependent signaling pathway.

Authors:  O Takeuchi; A Kaufmann; K Grote; T Kawai; K Hoshino; M Morr; P F Mühlradt; S Akira
Journal:  J Immunol       Date:  2000-01-15       Impact factor: 5.422

2.  Signaling pathways induced by lipoproteins derived from Mycoplasma salivarium and a synthetic lipopeptide (FSL-1) in normal human gingival fibroblasts.

Authors:  Jun-ichiro Nakamura; Ken-ichiro Shibata; Akira Hasebe; Takeshi Into; Tsuguo Watanabe; Noboru Ohata
Journal:  Microbiol Immunol       Date:  2002       Impact factor: 1.955

Review 3.  Signal transduction via P2-purinergic receptors for extracellular ATP and other nucleotides.

Authors:  G R Dubyak; C el-Moatassim
Journal:  Am J Physiol       Date:  1993-09

4.  MALP-2, a Mycoplasma lipopeptide with classical endotoxic properties: end of an era of LPS monopoly?

Authors:  C Galanos; M Gumenscheimer; P Mühlradt; E Jirillo; M Freudenberg
Journal:  J Endotoxin Res       Date:  2000

Review 5.  Endotoxin, toll-like receptor 4, and the afferent limb of innate immunity.

Authors:  B Beutler
Journal:  Curr Opin Microbiol       Date:  2000-02       Impact factor: 7.934

6.  Lipoproteins take their toll on the host.

Authors:  C A Janeway; R Medzhitov
Journal:  Curr Biol       Date:  1999-12-02       Impact factor: 10.834

7.  Establishment and characterization of a human acute monocytic leukemia cell line (THP-1).

Authors:  S Tsuchiya; M Yamabe; Y Yamaguchi; Y Kobayashi; T Konno; K Tada
Journal:  Int J Cancer       Date:  1980-08       Impact factor: 7.396

8.  Purification and partial biochemical characterization of a Mycoplasma fermentans-derived substance that activates macrophages to release nitric oxide, tumor necrosis factor, and interleukin-6.

Authors:  P F Mühlradt; M Frisch
Journal:  Infect Immun       Date:  1994-09       Impact factor: 3.441

9.  Increased proliferation rate of lymphoid cells transfected with the P2X(7) ATP receptor.

Authors:  O R Baricordi; L Melchiorri; E Adinolfi; S Falzoni; P Chiozzi; G Buell; F Di Virgilio
Journal:  J Biol Chem       Date:  1999-11-19       Impact factor: 5.157

10.  Oxidized ATP. An irreversible inhibitor of the macrophage purinergic P2Z receptor.

Authors:  M Murgia; S Hanau; P Pizzo; M Rippa; F Di Virgilio
Journal:  J Biol Chem       Date:  1993-04-15       Impact factor: 5.157

View more
  6 in total

1.  Synthesis and characterization of a dipalmitoylated lipopeptide derived from paralogous lipoproteins of Mycoplasma pneumoniae.

Authors:  Takeshi Into; Jun-ichi Dohkan; Megumi Inomata; Misako Nakashima; Ken-ichiro Shibata; Kenji Matsushita
Journal:  Infect Immun       Date:  2007-02-26       Impact factor: 3.441

2.  Adenosine diphosphate involvement in THP-1 maturation triggered by the contact allergen 1-fluoro-2,4-dinitrobenzene.

Authors:  J D Martins; A Silva; I Ferreira; M Gonçalo; J B A Custódio; M C Lopes; M R M Domingues; B M Neves; M T Cruz
Journal:  Toxicol Res (Camb)       Date:  2016-08-04       Impact factor: 3.524

3.  Correlation between chemical structure and biological activities of Porphyromonas gingivalis synthetic lipopeptide derivatives.

Authors:  Y Makimura; Y Asai; Y Taiji; A Sugiyama; R Tamai; T Ogawa
Journal:  Clin Exp Immunol       Date:  2006-10       Impact factor: 4.330

4.  Relationship between structures and biological activities of mycoplasmal diacylated lipopeptides and their recognition by toll-like receptors 2 and 6.

Authors:  Tsugumi Okusawa; Mari Fujita; Jun-Ichiro Nakamura; Takeshi Into; Motoaki Yasuda; Atsutoshi Yoshimura; Yoshitaka Hara; Akira Hasebe; Douglas T Golenbock; Manabu Morita; Yoshio Kuroki; Tomohiko Ogawa; Ken-Ichiro Shibata
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

5.  Multiple Signaling Molecules are Involved in Expression of CCL2 and IL-1β in Response to FSL-1, a Toll-Like Receptor 6 Agonist, in Macrophages.

Authors:  Keunsoo Won; Sun-Mi Kim; Sae-A Lee; Byung-Yong Rhim; Seong-Kug Eo; Koanhoi Kim
Journal:  Korean J Physiol Pharmacol       Date:  2012-12-10       Impact factor: 2.016

6.  Autocrine regulation of macrophage activation via exocytosis of ATP and activation of P2Y11 receptor.

Authors:  Hayato Sakaki; Mitsutoshi Tsukimoto; Hitoshi Harada; Yoshinori Moriyama; Shuji Kojima
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.